Get API key
Insider trading · Q3 2026 · CIK 1802369

ADARx Pharmaceuticals, Inc. (ADRX) insider trading.

In Q3 2026, insiders at ADARx Pharmaceuticals, Inc. reported 51 non-derivative transactions on 24 Forms 3, 4 and 5: 13 open-market purchases worth $87.7M and 0 sales.

Transactions
51
Purchases (P)
13
Sales (S)
0
Net shares, P minus S
5,161,516
Insiders
6
Last filed
2026-09-30

Insiders

InsiderRelationshipTransactionsBuysSales
OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCDirector, TenPercentOwner1130
Gordon Carl LDirector, TenPercentOwner1130
George SimeonDirector, TenPercentOwner930
Sr One Capital Management, LLCTenPercentOwner930
LAV Fund VI, L.P. / LAV Fund VI Opportunities, L.P. / LAV Biosciences Fund V, L.P.TenPercentOwner600
Chimovits ErezDirector510

Transactions

51 non-derivative rows, newest transaction first. Shares and prices as filed.
DateInsiderCodeSharesPriceOwned afterFiling
2026-09-28OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCC (A)564,187—14,025,280Form 4
2026-09-28OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCP (A)300,249$1714,325,529Form 4
2026-09-28OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCC (A)7,127,019—7,127,019Form 4
2026-09-28OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCC (A)1,333,975—8,460,994Form 4
2026-09-28OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCC (A)513,067—8,974,061Form 4
2026-09-28OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCC (A)256,448—9,230,509Form 4
2026-09-28OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCC (A)769,601—13,461,093Form 4
2026-09-28OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCC (A)2,000,962—12,691,492Form 4
2026-09-28OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCC (A)10,690,530—10,690,530Form 4
2026-09-28OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCP (A)61,516$179,292,025Form 4
2026-09-28OrbiMed Genesis GP LLC / OrbiMed Israel GP II, L.P. / OrbiMed Capital GP VII LLC / OrbiMed Advisors Israel II Ltd / ORBIMED ADVISORS LLCP (A)588,235$17588,235Form 4
2026-09-28Gordon Carl LC (A)10,690,530—10,690,530Form 4
2026-09-28Gordon Carl LC (A)2,000,962—12,691,492Form 4
2026-09-28Gordon Carl LC (A)769,601—13,461,093Form 4
2026-09-28Gordon Carl LC (A)564,187—14,025,280Form 4
2026-09-28Gordon Carl LP (A)300,249$1714,325,529Form 4
2026-09-28Gordon Carl LP (A)588,235$17588,235Form 4
2026-09-28Gordon Carl LC (A)1,333,975—8,460,994Form 4
2026-09-28Gordon Carl LC (A)513,067—8,974,061Form 4
2026-09-28Gordon Carl LC (A)256,448—9,230,509Form 4
2026-09-28Gordon Carl LP (A)61,516$179,292,025Form 4
2026-09-28Gordon Carl LC (A)7,127,019—7,127,019Form 4
2026-09-28Chimovits ErezC (A)7,127,019—7,127,019Form 4
2026-09-28Chimovits ErezC (A)1,333,975—8,460,994Form 4
2026-09-28Chimovits ErezP (A)61,516$179,292,025Form 4
2026-09-28Chimovits ErezC (A)256,448—9,230,509Form 4
2026-09-28Chimovits ErezC (A)513,067—8,974,061Form 4
2026-09-28George SimeonP (A)592,593$17592,593Form 4
2026-09-28George SimeonC (A)169,001—1,836,469Form 4
2026-09-28George SimeonC (A)1,667,468—1,667,468Form 4
2026-09-28George SimeonP (A)414,814$171,953,505Form 4
2026-09-28George SimeonC (A)1,538,691—1,538,691Form 4
2026-09-28George SimeonP (A)592,593$175,554,094Form 4
2026-09-28George SimeonC (A)512,897—4,961,501Form 4
2026-09-28George SimeonC (A)1,113,666—4,448,604Form 4
2026-09-28George SimeonC (A)3,334,938—3,334,938Form 4
2026-09-28Sr One Capital Management, LLCC (A)1,538,691—1,538,691Form 4
2026-09-28Sr One Capital Management, LLCC (A)512,897—4,961,501Form 4
2026-09-28Sr One Capital Management, LLCC (A)1,113,666—4,448,604Form 4
2026-09-28Sr One Capital Management, LLCC (A)3,334,938—3,334,938Form 4
2026-09-28Sr One Capital Management, LLCP (A)414,814$171,953,505Form 4
2026-09-28Sr One Capital Management, LLCC (A)1,667,468—1,667,468Form 4
2026-09-28Sr One Capital Management, LLCC (A)169,001—1,836,469Form 4
2026-09-28Sr One Capital Management, LLCP (A)592,593$17592,593Form 4
2026-09-28Sr One Capital Management, LLCP (A)592,593$175,554,094Form 4
2026-09-28LAV Fund VI, L.P. / LAV Fund VI Opportunities, L.P. / LAV Biosciences Fund V, L.P.C (A)513,067—11,089,311Form 4
2026-09-28LAV Fund VI, L.P. / LAV Fund VI Opportunities, L.P. / LAV Biosciences Fund V, L.P.C (A)8,908,775—8,908,775Form 4
2026-09-28LAV Fund VI, L.P. / LAV Fund VI Opportunities, L.P. / LAV Biosciences Fund V, L.P.C (A)307,738—307,738Form 4
2026-09-28LAV Fund VI, L.P. / LAV Fund VI Opportunities, L.P. / LAV Biosciences Fund V, L.P.C (A)153,868—11,243,179Form 4
2026-09-28LAV Fund VI, L.P. / LAV Fund VI Opportunities, L.P. / LAV Biosciences Fund V, L.P.C (A)307,738—307,738Form 4
2026-09-28LAV Fund VI, L.P. / LAV Fund VI Opportunities, L.P. / LAV Biosciences Fund V, L.P.C (A)1,667,469—10,576,244Form 4

Transaction codes in this quarter

C: 38P: 13

Get ADRX insider transactions through the API

Request with your API key
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1802369&limit=100" \
  -H "Authorization: Bearer $SEC_API_KEY"

Insider trading API guide · ADRX company page · ADARx Pharmaceuticals, Inc. on SEC.gov

Questions

Are insiders buying or selling ADARx Pharmaceuticals, Inc. (ADRX)?

In Q3 2026, insiders at ADARx Pharmaceuticals, Inc. reported 51 non-derivative transactions on 24 Forms 3, 4 and 5: 13 open-market purchases worth $87.7M and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.

Where do these ADARx Pharmaceuticals, Inc. insider trades come from?

From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.

Source: SEC Insider Transactions Data Sets, Q3 2026, retrieved 2026-10-27. Footnotes, derivative holdings and amendments are in the linked filings. Not investment advice.

Plain-text version for agents and LLMs: /insider-trading/adrx.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.